Growth hormone secretagogues — compounds that stimulate the pituitary to release GH — have existed since the 1970s. The first-generation compounds (GHRP-6, GHRP-2, Hexarelin) were effective at releasing GH but came with a pharmacological problem: they also raised cortisol, prolactin, and aldosterone. For researchers trying to study GH-specific biology, these off-target hormonal effects confounded their experiments.

Ipamorelin, described in a landmark 1998 paper by Raun et al., solved this problem. In dose-response studies across multiple species, Ipamorelin stimulated GH release at levels comparable to older GHRPs while producing no statistically significant changes in cortisol, prolactin, or aldosterone — even at supraphysiological doses. This selectivity was unprecedented in the GHRP class.¹

The practical consequence: researchers using Ipamorelin can attribute observed effects to GH signaling specifically, without the confounding variable of cortisol elevation (which affects metabolism, immunity, and behavior) or prolactin elevation (which affects reproductive biology and immune function).

Ipamorelin acts on the GHS-R1a receptor — the same receptor activated by ghrelin, the "hunger hormone" produced primarily in the stomach. GHS-R1a is expressed on pituitary somatotroph cells, where its activation triggers GH release through calcium influx and protein kinase C signaling.²

But GHS-R1a isn't only in the pituitary. It's expressed in the hypothalamus (appetite regulation), hippocampus (memory and learning), substantia nigra (dopaminergic function), and peripheral tissues including the heart and adipose tissue. This distribution means GHS-R1a agonists potentially affect more than just GH release — a consideration for research design.

Ipamorelin's selectivity for GH release over other hormones is attributed to its binding kinetics at GHS-R1a. While it activates the same receptor as less selective GHRPs, its interaction appears to preferentially engage the signaling pathways that lead to GH release while minimizing activation of pathways that stimulate ACTH (the cortisol precursor) and prolactin release.

A critical distinction in GH biology is the release pattern. Natural GH secretion is pulsatile — occurring in bursts throughout the day, with the largest pulses during deep sleep. This pulsatile pattern is not arbitrary; research has shown that the biological effects of GH depend on the pattern of exposure, not just the total amount.³

Exogenous GH (injected human growth hormone) produces sustained elevation — a flat, continuous level rather than pulses. This sustained pattern activates different downstream pathways than pulsatile exposure. Some researchers believe that sustained GH elevation contributes to the side effects associated with exogenous GH therapy.

Ipamorelin stimulates the pituitary to release GH in its natural pulsatile pattern — the gland produces a burst, then returns to baseline. This makes Ipamorelin a more physiologically relevant research tool than exogenous GH for studying GH biology under near-natural conditions.

Ipamorelin is frequently studied in combination with GHRH analogs (Sermorelin, CJC-1295). The rationale is straightforward: GHRH and GHRP act through different receptors on the same cell type (pituitary somatotrophs) to produce GH release through complementary mechanisms.

GHRH (acting through the GHRH receptor) stimulates GH gene transcription and primes vesicles for release. GHRP/Ipamorelin (acting through GHS-R1a) amplifies the release signal, increasing the amount of GH released per pulse. In animal models, the combination consistently produces GH output greater than either compound alone.⁴

The OSYRIS CJC NO DAC/Ipamorelin Blend provides this combination in a single vial for research protocols studying synergistic GH release.

Beyond GH release kinetics, Ipamorelin has been studied for downstream effects on body composition and bone density.

Body composition. Chronic Ipamorelin administration in rodent models increased lean body mass and reduced adiposity without changes in food intake. The effects were attributed to GH-mediated stimulation of protein synthesis (lean mass) and lipolysis (fat reduction).⁵

Bone density. In ovariectomized rat models (postmenopausal bone loss), Ipamorelin treatment increased bone mineral content and improved bone strength. GH stimulates IGF-1 production in bone, which promotes osteoblast activity and bone formation. The fact that Ipamorelin-stimulated pulsatile GH produced measurable bone effects confirms that the GH release is biologically functional.⁶

No human efficacy trials. Ipamorelin has been studied in human pharmacokinetic/pharmacodynamic studies (confirming GH release in humans) but not in efficacy trials for specific outcomes.

GHS-R1a complexity. The ghrelin receptor has constitutive activity (it's partially active even without a ligand) and can form heterodimers with other receptors, creating pharmacological complexity that isn't fully characterized.

Downstream specificity. While Ipamorelin selectively releases GH, the downstream effects of that GH are not selective — GH affects multiple tissues. The selectivity is in the release, not in the downstream biology.